MetaCap

Harmony Biosciences (HRMY) vs Palvella Therapeutics (PVLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palvella Therapeutics (PVLA) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 51.8% versus a loss of 5.0%. Over five years, HRMY leads with a -13.2% price change compared with -48.4% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.09 billion vs $1.91 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRMY-5.01%PVLA+51.82%
+92%+32%-28%
Nov 21, 20251 yearNov 20, 2026
HRMY-15.92%PVLA-51.61%
+64%-21%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRMY versus PVLA key metrics
MetricHRMYPVLA
Share price$32.59$142.85
Market cap$1.91B$2.09B
1-day change-1.18%-2.00%
YTD return-12.91%+36.48%
1-year return-5.01%+51.82%
5-year return-13.21%-48.39%
P/E ratio (TTM)10.79—
Forward P/E5.37—
EPS (TTM)$3.02$-5.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$868.45M—
Revenue growth (YoY)+21.51%—
Net income (latest FY)$158.69M$-41.72M
Gross margin77.16%—
Operating margin24.00%—
Net margin18.27%—
52-week high$43.49$179.95
52-week low$25.90$72.23
Distance from 52-week high-25.06%-20.62%
Analyst consensusbuystrong_buy
Avg. price target upside+47.53%+63.42%
Average volume1.01M240.41K
Shares outstanding58.72M14.62M
Employees29329
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PVLA has outperformed HRMY by 56.8 percentage points over the past year.

About Harmony Biosciences

HRMY stock →

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

About Palvella Therapeutics

PVLA stock →

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

HRMY vs PVLA FAQ

Which is bigger, Harmony Biosciences or Palvella Therapeutics?

Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.09B compared with $1.91B for Harmony Biosciences (HRMY).

Which stock has performed better over the past year, HRMY or PVLA?

PVLA returned +51.82% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.

Are Harmony Biosciences and Palvella Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons